New product for the treatment of rheumatoid arthritis

Organon Canada announced Oct. 26 the availability of its Hadlima product for the treatment of rheumatoid arthritis.

It can also be used for polyarticular juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, Crohn’s disease in adults, ulcerative colitis, hidradenitis suppurativa in adults and adolescents, plaque psoriasis, and uveitis in adults and children.

“The introduction of a citrate-free, highly concentrated preparation […] “means Canadians with certain chronic autoimmune diseases, including inflammatory bowel disease, have access to more advanced treatment options,” says Dr.R Peter Lakatos, gastroenterologist at McGill University Health Center, via press release:

Please note that this is a biosimilar product to Humira, in a citrate-free version and with a new preparation in a higher concentration. The Hadlima product had already been approved by Health Canada in its low concentration form in May 2018.

Hadlima was developed and manufactured by Samsung Bioepis. It is a partner of Organon, which has also developed and manufactured its other biosimilar products, including Ontruzant, Aybintio, Brenzys and Renflexis. (NP)

Jordan Johnson

Award-winning entrepreneur. Baconaholic. Food advocate. Wannabe beer maven. Twitter ninja.

Leave a Reply

Your email address will not be published. Required fields are marked *